GLA 抗体 (AA 322-409)
Quick Overview for GLA 抗体 (AA 322-409) (ABIN7114447)
抗原
See all GLA 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 322-409
-
原理
- GLA antibody
-
纯化方法
- Immunogen affinity purified
-
纯度
- ≥95 % as determined by SDS-PAGE
-
免疫原
-
Immunogen sequence: 322-409aa
Immunogen: galactosidase, alpha
-
亚型
- IgG
-
-
-
-
应用备注
- WB: 1:500-1:5000, IHC: 1:20-1:200, IP: 1:500-1:5000
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
注意事项
- Avoid repeated freeze / thaw cycles.
-
储存条件
- -20 °C
-
储存方法
- -20°C for 12 months
-
有效期
- 12 months
-
-
- GLA (Galactosidase, alpha (GLA))
-
别名
- GLA
-
背景
-
Synonyms: Alpha-galactosidase A|Alpha-D-galactosidase A|Alpha-D-galactoside galactohydrolase|Galactosylgalactosylglucosylceramidase GLA|Melibiase|GLA
Background: GLA, also named as Melibiase, Agalsidas and Alpha-galactosidase A, Belongs to the glycosyl hydrolase 27 family. It hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.
-
分子量
- 49 kDa
-
基因ID
- 2717
-
UniProt
- P06280
-
途径
- SARS-CoV-2 Protein Interactome
抗原
-